Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000905718-19-000210
Form Type:
13G Filing
Publication Date:
2019-02-14 16:09:18
Filed By:
Newtyn Management
Company:
Recro Pharma Inc. (NASDAQ:REPH)
Filing Date:
2019-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Newtyn Management 1,600,000 0 1,600,000 0 1,600,000 7.4%
Filing

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No.    )*

 

 

RECRO pharma, INC.

(Name of Issuer)

 

Common Stock, $0.01 par value per share

(Title of Class of Securities)

 

75629F109

(CUSIP Number)

 

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

 

[X] Rule 13d-1(b)

[   ] Rule 13d-1(c)

[   ] Rule 13d-1(d)

  

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

 

 

CUSIP No.  75629F109
(1) Names of Reporting Persons
  Newtyn Management, LLC  
(2) Check the Appropriate Box if a Member of a Group (a) [    ]  
  (b) [    ]  
     
(3) SEC Use Only
(4) Citizenship or Place of Organization
  New York  
Number of Shares Beneficially Owned by Each Reporting Person With:
  (5) Sole Voting Power: 1,600,000*  
  (6) Shared Voting Power: 0    
  (7) Sole Dispositive Power: 1,600,000*  
  (8) Shared Dispositive Power: 0    
       
(9) Aggregate Amount Beneficially Owned by Each Reporting Person
  1,600,000*  
(10) Check if the Aggregate Amount  in Row (9) Excludes Certain Shares (See Instructions):
  [    ]  
(11) Percent of Class Represented by Amount in Row (9)
  7.4%*  
(12) Type of Reporting Person (See Instructions)
  IA  
               

* Beneficial ownership percentage is based upon 21,477,498 shares of Common Stock, $0.01 par value per share (“Common Stock”), of Recro Pharma, Inc., a Pennsylvania corporation (the “Company”), issued and outstanding as of November 5, 2018, based on information reported by the Company in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018, filed with the Securities and Exchange Commission on November 7, 2018. Newtyn Management, LLC (the “Reporting Person”) is the investment manager to Newtyn Partners, LP (“NP”) and Newtyn TE Partners, LP (“NTE”). As of December 31, 2018, NP held 904,098 shares of Common Stock and NTE held 695,902 shares of Common Stock.

 

The Reporting Person, as the investment manager to NP and NTE, possesses the sole power to direct the vote and the sole power to direct the disposition of the 1,600,000 shares of Common Stock held in the aggregate by NP and NTE. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Person may be deemed to beneficially own 1,600,000 shares of Common Stock, or 7.4% of the shares of Common Stock deemed to be issued and outstanding as of December 31, 2018.  

 

  


Item 1(a).  Name Of Issuer.  Recro Pharma, Inc. (the “Company”)
   
Item 1(b).  Address of Issuer’s Principal Executive Offices.
 

490 Lapp Road, Malvern, Pennsylvania 19355

 

Item 2(a).  Name of Person Filing.
 

This report on Schedule 13G (this “Schedule 13G”) is being filed by Newtyn Management, LLC, a New York limited liability company and the investment manager to (a) Newtyn Partners, LP (“NP”), which is the holder of 904,098 shares of Common Stock, $0.01 par value per share (“Common Stock”), of the Company reported on this Schedule 13G, and (b) Newtyn TE Partners, LP (“NTE”), which is the holder of 695,902 shares of Common Stock of the Company reported on this Schedule 13G.

 

The 1,600,000 shares of Common Stock held in the aggregate by NP and NTE, which constitutes 7.4% of the shares of Common Stock deemed to be issued and outstanding as of December 31, 2018, may be deemed to be beneficially owned indirectly by Newtyn Management, LLC, as the investment manager to NP and NTE.

 

Item 2(b).  Address of Principal Business Office or, if None, Residence.
 

The address for the Reporting Person is 405 Park Avenue, Suite 1104, New York, New York 10022.

 

Item 2(c).  Citizenship.
 

Newtyn Management, LLC is organized under the laws of the State of New York.

 

Item 2(d).  Title of Class of Securities.
   Common Stock, $0.01 par value per share.
Item 2(e).  CUSIP No.
   75629F109

 

Item 3.  If This Statement Is Filed Pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:
       Not Applicable.    

   

  

Item 4.  Ownership.

 
     
  (a)     Amount Beneficially Owned: 1,600,000*    
  (b)    Percent of Class: 7.4%*    
  (c)     Number of Shares as to which such person has:      
  (i)     Sole power to vote or to direct the vote: 1,600,000*  
  (ii)     Shared power to vote or to direct the vote: 0    
  (iii)     Sole power to dispose or to direct the disposition of: 1,600,000*  
  (iv)     Shared power to dispose or to direct the disposition of: 0  
           

 ___________________________________________________________

 *     This Schedule 13G is being filed by Newtyn Management, LLC, a New York limited liability company and the investment manager to (a) NP, which is the holder of 904,098 shares of Common Stock of the Company reported on this Schedule 13G, and (b) NTE, which is the holder of 695,902 shares of Common Stock of the Company reported on this Schedule 13G.

  

The 1,600,000 shares of Common Stock held in the aggregate by NP and NTE, which constitutes 7.4% of the shares of Common Stock deemed to be issued and outstanding as of December 31, 2018, may deemed to be beneficially owned indirectly by Newtyn Management, LLC, as the investment manager to NP and NTE.

 

The foregoing beneficial ownership percentage is based upon information reported by the Company in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2018, filed with the Securities and Exchange Commission on November 7, 2018.

  

Item 5.  Ownership of Five Percent or Less of a Class.
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  [   ]
Item 6.  Ownership of More Than Five Percent on Behalf of Another Person.
   Not Applicable.
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
   Not Applicable.
Item 8.  Identification and Classification of Members of the Group.
   Not Applicable.
Item 9.  Notice of Dissolution of Group.
   Not Applicable.
Item 10.  Certification.
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  February 14, 2019  
     
  NEWTYN MANAGEMENT, LLC  
     
     
  By: /s/ Eugene Dozortsev  
  Name: Eugene Dozortsev  
  Title: Authorized Signatory  

 

  

Attention: Intentional misstatements or omissions of fact constitute

Federal criminal violations (See 18 U.S.C. 1001)